Form 4: Teva Executive Sells Shares After RSU Vesting

Teva's EVP of Global R&D and Chief Medical Officer, Eric A. Hughes, sold shares to cover tax obligations following the vesting of restricted stock units.

Summary

• Eric A. Hughes, Executive Vice President, Global R&D and Chief Medical Officer of Teva Pharmaceutical Industries Ltd., reported transactions on March 3, 2026.
• Hughes acquired a total of 166,378 Ordinary Shares through the vesting of Restricted Share Units (RSUs), comprising 24,900 RSUs and 141,478 performance-based RSUs.
• Concurrently, Hughes disposed of a total of 80,762 Ordinary Shares at a weighted average price of $32.3599 per share.
• These sales were conducted to cover tax withholding obligations associated with the RSU vesting.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a routine executive compensation transaction involving RSU vesting and subsequent tax-related share sales, which is pre-planned and common practice.

Positives

• Vesting of 166,378 Restricted Share Units (RSUs) indicates the satisfaction of performance and time-based criteria for executive compensation.
• The performance-based RSUs (141,478 units) were earned on January 27, 2026, following the satisfaction of specific performance criteria certified by the Human Resources and Compensation Committee.

Negatives

• The sale of 80,762 Ordinary Shares by an executive, even for tax purposes, represents a reduction in direct beneficial ownership.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that the vesting of Restricted Share Units (RSUs) and subsequent sales to cover tax obligations are a common and routine component of executive compensation packages across the pharmaceutical industry. This type of transaction is standard practice for executives receiving equity-based awards.

Comparison to Industry Standards

• The structure of executive equity compensation, involving RSUs that vest over time and often include performance criteria, aligns with common practices observed in major pharmaceutical companies such as Pfizer, Merck, and Johnson & Johnson.
• The use of a Rule 10b5-1 trading plan for pre-planned sales to cover tax liabilities is a widely adopted corporate governance measure among public company executives to avoid accusations of insider trading and ensure compliance with SEC regulations.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, pre-planned executive compensation event and not indicative of a change in company fundamentals or executive sentiment beyond compensation.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Future vesting of 24,901 Restricted Share Units is scheduled for March 3, 2027.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of Restricted Share Units and a subsequent sale of shares to cover tax obligations, executed under a pre-established 10b5-1 plan. Such transactions are standard executive compensation events and do not typically signal a change in the company's fundamental outlook or the executive's long-term view of the company. Therefore, it does not provide new information that would warrant a change in investment recommendation, maintaining a 'hold' stance.

Keywords

Teva Pharmaceutical Industries, TEVA, Form 4, Insider Transaction, Restricted Share Units, RSU Vesting, Executive Compensation, Share Sale, Rule 10b5-1 Plan, Eric A. Hughes